A complete application in a minute — tailored resume and cover letter, ready to send.
Quanterix, a global leader in ultra-sensitive biomarker detection, seeks a Business Development Manager in Houston, TX to drive growth across RUO markets including academia, government, and biopharmaceutical accounts. You will translate complex immunoassay capabilities into compelling value propositions and build long-lasting collaborations to expand the Simoa portfolio.
This technical sales role requires 6–8 years of relevant experience, strong relationships in life science sectors, excellent
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue-advancing precision medicine from discovery to diagnostics.
To continue our extraordinary growth, we are hiring a Business Development Manager for Houston, Texas. This position will be part of our Commercial Team. This role requires familiarity with current Immunoassay platforms and the candidate must be able to convincingly articulate the benefits of the Quanterix Simoa product. The ideal candidate for this role will be a highly technical, scientific sales professional, who has a passion for finding new customers, building new relationships, maintaining and expanding business within current accounts, and has a desire to expand and grow Quanterix business.
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Our industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology, and infectious disease.
Akoya's spatial phenotyping platforms help researchers visualize and measure how cells organize and interact within tissue to influence disease progression and therapeutic response. From discovery through clinical research, Akoya offers a full continuum of solutions, including PhenoCycler, PhenoImager Fusion and HT, and PhenoCode Panels. As part of Quanterix, Akoya complements a leading portfolio of ultra-sensitive biomarker detection technologies, together enabling a more complete view of biology and disease across both tissue and blood.
At Quanterix, our values are based on: Team, Innovation, Customer and Owner.
Quanterix is committed to a Diverse and Inclusive workplace. We strive to recruit candidates who will bring inclusive mindsets and contribute to our values.
Quanterix is an Equal Opportunity Employer and does not discriminate based on race, national origin, gender, gender identity, sexual orientation, protected veteran status, disability, age, or other legally protected status. Quanterix will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.